<p>REGENXBIO Inc. (NASDAQ:RGNX - 获取免费报告) 的股价在周二上涨了 10.7%，因为华尔街 Zen 将该股票的评级从卖出上调至持有。该公司股价最高达到$13.59，最后交易价为$13.54。在交易过程中，约有 409,030 股易手，较 847,395 股的日均交易量下降了 52%。该股票之前的收盘价为$12.23。</p>
<p>其他一些股票研究分析师也对 RGNX 发表了看法。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 REGENXBIO 股票的 “卖出（d-）” 评级。加拿大皇家银行在 11 月 7 日的报告中将 REGENXBIO 的目标价从$17.00 上调至$19.00，并给予该公司 “跑赢大盘” 的评级。HC Wainwright 在 10 月 7 日的报告中重新发布了 “买入” 评级，并设定了$34.00 的目标价。巴克莱在 8 月 8 日的研究报告中将 REGENXBIO 的目标价从$50.00 下调至$37.00，并对该公司设定了 “增持” 评级。最后，Chardan Capital 在 11 月 20 日的研究报告中重申了 “买入” 评级，并设定了$52.00 的目标价。五位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为$28.63。</p>
<p><strong>获取我们关于 RGNX 的最新研究报告</strong></p>
<h2>REGENXBIO 的内部活动</h2>
<p>在相关消息中，首席执行官 Curran Simpson 在 10 月 9 日的交易中出售了 20,811 股公司的股票。该股票以平均价格$12.62 出售，总交易额为$262,634.82。交易完成后，首席执行官持有 216,162 股公司股票，价值$2,727,964.44。这笔交易代表了他们持股比例的 8.78% 的减少。该出售在向 SEC 的文件中披露，相关文件可通过 SEC 网站获取。在过去 90 天内，内部人士已出售价值$416,598 的 36,169 股公司股票。目前，内部人士持有该股票的 12.79%。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金最近增加或减少了对该公司的持股。摩根大通在第三季度将其在 REGENXBIO 的持股提高了 4.8%。摩根大通目前持有 4,037,248 股该生物技术公司的股票，价值$38,959,000，在上个季度又购买了 185,223 股。先锋集团在第一季度将其在 REGENXBIO 的持股提高了 16.3%。先锋集团目前持有 3,472,988 股该生物技术公司的股票，价值$24,832,000，在此期间又购买了 487,036 股。Geode Capital Management 在第二季度将其在 REGENXBIO 的持股提高了 1.9%。Geode Capital Management 目前持有 1,128,521 股该生物技术公司的股票，价值$9,267,000，在上个季度又收购了 21,575 股。Integral Health Asset Management 在第三季度将其在 REGENXBIO 的持股提高了 57.1%。Integral Health Asset Management 目前持有 1,100,000 股该生物技术公司的股票，价值$10,615,000，在此期间又收购了 400,000 股。最后，AQR Capital Management 在第二季度将其在 REGENXBIO 的持股提高了 49.9%。AQR Capital Management 目前持有 930,196 股该生物技术公司的股票，价值$7,637,000，在上个季度又收购了 309,601 股。机构投资者和对冲基金持有该公司 88.08% 的股票。</p>
<h2>REGENXBIO 上涨 9.8%</h2>
<p>该公司的 50 日移动平均线为$11.21，200 日移动平均线为$9.69。该公司的市值为$679.83 百万，市盈率为-3.87，贝塔值为 1.22。</p>
<p>REGENXBIO (NASDAQ:RGNX - 获取免费报告) 最近在 11 月 6 日发布了其财报。这家生物技术公司报告本季度每股收益为 ($1.20)，超出分析师共识预期的 ($1.38) $0.18。该公司本季度的收入为$29.73 百万，而共识预期为$24.41 百万。REGENXBIO 的股本回报率为-78.29%，净利润率为-110.29%。平均而言，研究分析师预测 REGENXBIO Inc.在当前财政年度将发布-4.84 的每股收益。</p>
<h2>REGENXBIO 公司简介</h2>
<p>(获取免费报告)</p>
<p>REGENXBIO Inc 是一家临床阶段的生物技术公司，提供基因疗法，将功能基因传递给美国的遗传缺陷细胞。其基因疗法产品候选者基于 NAV 技术平台，这是一种专有的腺病毒相关病毒基因传递平台。该公司的产品管线包括用于治疗湿性年龄相关性黄斑变性、糖尿病视网膜病变和其他慢性视网膜疾病的 ABBV-RGX-314，以及正在进行 I/II 期临床试验的 RGX-202，用于治疗杜氏肌营养不良症。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票超过 REGENXBIO</li>
<li>投资旅游股票的好处</li>
<li>错过了人工智能的繁荣？这两只被压制的股票可能是你的第二次机会</li>
<li>消费者价格指数测量什么？</li>
<li>六旗的新领导者：过山车结束了吗？</li>
<li>股票交易术语 - 每个投资者需要了解的股票术语</li>
<li>百度可能成为全球人工智能的黑马的三个理由</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 REGENXBIO 吗？</h2>
<p>在你考虑 REGENXBIO 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 REGENXBIO 并不在名单上。</p>
<p>虽然 REGENXBIO 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RGNX

<p>REGENXBIO 的股票在华尔街 Zen 将其评级从卖出上调至持有后上涨了 10.7%。该股票交易价格为 13.54 美元，交易量显著减少。分析师的评级各不相同，普遍共识为 “适度买入”，目标价格为 28.63 美元。还注意到内部交易和机构投资，摩根大通、先锋集团等持有大量股份。该公司报告的收益好于预期，但股本回报率为负，净利润率也不理想</p>

<p>REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report)'s share price was up 10.7% on Tuesday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The company traded as high as $13.59 and last traded at $13.54. Approximately 409,030 shares changed hands during trading, a decline of 52% from the average daily volume of 847,395 shares. The stock had previously closed at $12.23.</p>
<div class="lb-trans"><p>REGENXBIO Inc. (NASDAQ:RGNX - 获取免费报告) 的股价在周二上涨了 10.7%，因为华尔街 Zen 将该股票的评级从卖出上调至持有。该公司股价最高达到$13.59，最后交易价为$13.54。在交易过程中，约有 409,030 股易手，较 847,395 股的日均交易量下降了 52%。该股票之前的收盘价为$12.23。</p>
</div><p>A number of other equities research analysts have also weighed in on RGNX. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of REGENXBIO in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, November 7th. HC Wainwright reissued a &#34;buy&#34; rating and set a $34.00 price objective on shares of REGENXBIO in a report on Tuesday, October 7th. Barclays dropped their target price on shares of REGENXBIO from $50.00 to $37.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, August 8th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, November 20th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $28.63.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也对 RGNX 发表了看法。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 REGENXBIO 股票的 “卖出（d-）” 评级。加拿大皇家银行在 11 月 7 日的报告中将 REGENXBIO 的目标价从$17.00 上调至$19.00，并给予该公司 “跑赢大盘” 的评级。HC Wainwright 在 10 月 7 日的报告中重新发布了 “买入” 评级，并设定了$34.00 的目标价。巴克莱在 8 月 8 日的研究报告中将 REGENXBIO 的目标价从$50.00 下调至$37.00，并对该公司设定了 “增持” 评级。最后，Chardan Capital 在 11 月 20 日的研究报告中重申了 “买入” 评级，并设定了$52.00 的目标价。五位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为$28.63。</p>
</div><p><strong>Get Our Latest Research Report on RGNX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 RGNX 的最新研究报告</strong></p>
</div><h2>Insider Activity at REGENXBIO</h2>
<div class="lb-trans"><h2>REGENXBIO 的内部活动</h2>
</div><p>In related news, CEO Curran Simpson sold 20,811 shares of the firm's stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the completion of the transaction, the chief executive officer owned 216,162 shares of the company's stock, valued at $2,727,964.44. This trade represents a 8.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 36,169 shares of company stock worth $416,598. 12.79% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Curran Simpson 在 10 月 9 日的交易中出售了 20,811 股公司的股票。该股票以平均价格$12.62 出售，总交易额为$262,634.82。交易完成后，首席执行官持有 216,162 股公司股票，价值$2,727,964.44。这笔交易代表了他们持股比例的 8.78% 的减少。该出售在向 SEC 的文件中披露，相关文件可通过 SEC 网站获取。在过去 90 天内，内部人士已出售价值$416,598 的 36,169 股公司股票。目前，内部人士持有该股票的 12.79%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase &amp; Co. lifted its holdings in shares of REGENXBIO by 4.8% during the third quarter. JPMorgan Chase &amp; Co. now owns 4,037,248 shares of the biotechnology company's stock valued at $38,959,000 after purchasing an additional 185,223 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of REGENXBIO by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock worth $24,832,000 after buying an additional 487,036 shares during the period. Geode Capital Management LLC increased its position in shares of REGENXBIO by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,128,521 shares of the biotechnology company's stock worth $9,267,000 after acquiring an additional 21,575 shares in the last quarter. Integral Health Asset Management LLC raised its holdings in shares of REGENXBIO by 57.1% during the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $10,615,000 after acquiring an additional 400,000 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of REGENXBIO by 49.9% in the 2nd quarter. AQR Capital Management LLC now owns 930,196 shares of the biotechnology company's stock valued at $7,637,000 after acquiring an additional 309,601 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了对该公司的持股。摩根大通在第三季度将其在 REGENXBIO 的持股提高了 4.8%。摩根大通目前持有 4,037,248 股该生物技术公司的股票，价值$38,959,000，在上个季度又购买了 185,223 股。先锋集团在第一季度将其在 REGENXBIO 的持股提高了 16.3%。先锋集团目前持有 3,472,988 股该生物技术公司的股票，价值$24,832,000，在此期间又购买了 487,036 股。Geode Capital Management 在第二季度将其在 REGENXBIO 的持股提高了 1.9%。Geode Capital Management 目前持有 1,128,521 股该生物技术公司的股票，价值$9,267,000，在上个季度又收购了 21,575 股。Integral Health Asset Management 在第三季度将其在 REGENXBIO 的持股提高了 57.1%。Integral Health Asset Management 目前持有 1,100,000 股该生物技术公司的股票，价值$10,615,000，在此期间又收购了 400,000 股。最后，AQR Capital Management 在第二季度将其在 REGENXBIO 的持股提高了 49.9%。AQR Capital Management 目前持有 930,196 股该生物技术公司的股票，价值$7,637,000，在上个季度又收购了 309,601 股。机构投资者和对冲基金持有该公司 88.08% 的股票。</p>
</div><h2>REGENXBIO Trading Up 9.8%</h2>
<div class="lb-trans"><h2>REGENXBIO 上涨 9.8%</h2>
</div><p>The company's 50-day moving average is $11.21 and its 200 day moving average is $9.69. The firm has a market cap of $679.83 million, a PE ratio of -3.87 and a beta of 1.22.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为$11.21，200 日移动平均线为$9.69。该公司的市值为$679.83 百万，市盈率为-3.87，贝塔值为 1.22。</p>
</div><p>REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating analysts' consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%. On average, research analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>REGENXBIO (NASDAQ:RGNX - 获取免费报告) 最近在 11 月 6 日发布了其财报。这家生物技术公司报告本季度每股收益为 ($1.20)，超出分析师共识预期的 ($1.38) $0.18。该公司本季度的收入为$29.73 百万，而共识预期为$24.41 百万。REGENXBIO 的股本回报率为-78.29%，净利润率为-110.29%。平均而言，研究分析师预测 REGENXBIO Inc.在当前财政年度将发布-4.84 的每股收益。</p>
</div><h2>REGENXBIO Company Profile</h2>
<div class="lb-trans"><h2>REGENXBIO 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.</p>
<div class="lb-trans"><p>REGENXBIO Inc 是一家临床阶段的生物技术公司，提供基因疗法，将功能基因传递给美国的遗传缺陷细胞。其基因疗法产品候选者基于 NAV 技术平台，这是一种专有的腺病毒相关病毒基因传递平台。该公司的产品管线包括用于治疗湿性年龄相关性黄斑变性、糖尿病视网膜病变和其他慢性视网膜疾病的 ABBV-RGX-314，以及正在进行 I/II 期临床试验的 RGX-202，用于治疗杜氏肌营养不良症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than REGENXBIO</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Missed the AI Boom? These 2 Crushed Stocks Could Be Your Second Chance</li>
<li>What does consumer price index measure?</li>
<li>A New Leader at Six Flags: Is the Roller Coaster Over?</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>3 Reasons Baidu Could Be the Dark Horse of Global AI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 REGENXBIO</li>
<li>投资旅游股票的好处</li>
<li>错过了人工智能的繁荣？这两只被压制的股票可能是你的第二次机会</li>
<li>消费者价格指数测量什么？</li>
<li>六旗的新领导者：过山车结束了吗？</li>
<li>股票交易术语 - 每个投资者需要了解的股票术语</li>
<li>百度可能成为全球人工智能的黑马的三个理由</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in REGENXBIO Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 REGENXBIO 吗？</h2>
</div><p>Before you consider REGENXBIO, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 REGENXBIO 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 REGENXBIO 并不在名单上。</p>
</div><p>While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 REGENXBIO 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

REGENXBIO（纳斯达克代码：RGNX）在分析师上调评级后股价上涨 10.7%